We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

ALIFAX DIAG/SRE

Develops automated diagnostic instruments for ESR testing and Bacterial Culture read more Featured Products: More products

Download Mobile App




Rapid Method Developed for Direct Antimicrobial Susceptibility Testing

By LabMedica International staff writers
Posted on 23 Aug 2016
Rapid identification (ID) and antimicrobial susceptibility testing (AST) of the causative agent(s) of bloodstream infections (BSI) are essential for the timely selection of an appropriate antimicrobial therapy, which may result in a better outcome for patients and contribute to combat the emergence of antimicrobial resistance.

A method has been established able to provide rapid AST results, further referred to as direct AST. More...
To this aim, an approved system, initially conceived for urine screening, and for AST of bacterial isolates from urine was used. In order to adapt the system to rapid AST from positive blood cultures, two different protocols, protocol 1 (PR1) and protocol 2 (PR2), were evaluated.

Scientists at the University of Pisa (Italy) and their collaborators inoculated blood specimens from patients admitted to the Pisa University Hospital in the period July-December 2014, into blood culture bottles and transferred to the Bactec FX instrument (Becton Dickinson, Franklin Lakes, NJ, USA) for monitoring bacterial growth. From each patient, only the first positive blood culture (BC) apparently monomicrobial at the Gram staining was included in this study.

BC positive at the Bactec FX instrument were subjected to Gram staining and subcultured onto appropriate solid media. Isolated colonies were identified by MALDI-TOF (Bruker Daltonics, Bremen, Germany) and AST was performed by Vitek 2 (bioMérieux, Marcy l’Étoile, France). Direct AST of bacteria was performed by a Alfred 60AST automated bacterial culture device (Alifax SpA, Polverara, Italy) and carried out using two different protocols, PR1 and PR2. By PR1, bacteria were recovered from positive BC by serum separator tubes or by PR2 after a short-term subculture in liquid medium.

The direct MALDI-TOF method concordantly identified with the current method 97.5% of the Gram-negative bacteria and 96.1 % of the Gram-positive cocci contained in monomicrobial blood cultures. The direct AST by PR1 and PR2 for all isolate/antimicrobial agent combinations was concordant/correct with the current method for 87.8% and 90.5 % of Gram-negative bacteria and for 93.1% and 93.8 % of Gram-positive cocci, respectively. In particular, 100% categorical agreement was found with levofloxacin for Enterobacteriaceae by both PR1 and PR2, and 99.0% and 100 % categorical agreement was observed with linezolid for Gram-positive cocci by PR1 and PR2, respectively. There was no significant difference in accuracy between PR1 and PR2 for Gram-negative bacteria and Gram-positive cocci.

The authors concluded that their newly described method seems promising for providing accurate AST results. Most importantly, these results would be available in a few hours from blood culture positivity, which would help clinicians to promptly confirm or streamline an effective antibiotic therapy in patients with bloodstream infections. The study was published on August 12, 2016, in the journal BMC Microbiology.

Related Links:
University of Pisa
Becton Dickinson
Bruker Daltonics
bioMérieux
Alifax


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.